258 related articles for article (PubMed ID: 28800336)
1. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
Hendriksen RGF; Lionarons JM; Hendriksen JGM; Vles JSH; McAdam LC; Biggar WD
J Neuromuscul Dis; 2017; 4(3):217-236. PubMed ID: 28800336
[TBL] [Abstract][Full Text] [Related]
2. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
[TBL] [Abstract][Full Text] [Related]
3. A Mixed-Method Study Exploring Patient-Experienced and Caregiver-Reported Benefits and Side Effects of Corticosteroid Use in Duchenne Muscular Dystrophy.
Fischer R; Porter K; Donovan JM; Scavina MT; Armstrong N; Denger B; Hasham S; Peay H
J Neuromuscul Dis; 2023; 10(4):593-613. PubMed ID: 37182893
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
Wong BL; Christopher C
J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
[TBL] [Abstract][Full Text] [Related]
5. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Hirtz D; Shieh PB; Straub V; Childs AM; Ciafaloni E; Butterfield RJ; Horrocks I; Spinty S; Flanigan KM; Kuntz NL; Baranello G; Roper H; Morrison L; Mah JK; Manzur AY; McDonald CM; Schara U; von der Hagen M; Barohn RJ; Campbell C; Darras BT; Finkel RS; Vita G; Hughes I; Mongini T; Pegoraro E; Wicklund M; Wilichowski E; Bryan Burnette W; Howard JF; McMillan HJ; Thangarajh M; Griggs RC
Contemp Clin Trials; 2017 Jul; 58():34-39. PubMed ID: 28450193
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in children and adolescents with Duchenne muscular dystrophy.
Uzark K; King E; Cripe L; Spicer R; Sage J; Kinnett K; Wong B; Pratt J; Varni JW
Pediatrics; 2012 Dec; 130(6):e1559-66. PubMed ID: 23129083
[TBL] [Abstract][Full Text] [Related]
7. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.
Merlini L; Gennari M; Malaspina E; Cecconi I; Armaroli A; Gnudi S; Talim B; Ferlini A; Cicognani A; Franzoni E
Muscle Nerve; 2012 Jun; 45(6):796-802. PubMed ID: 22581531
[TBL] [Abstract][Full Text] [Related]
8. Development and content validation of the Muscular Dystrophy Child Health Index of Life with Disabilities questionnaire for children with Duchenne muscular dystrophy.
Propp R; McAdam L; Davis AM; Salbach NM; Weir S; Encisa C; Narayanan UG
Dev Med Child Neurol; 2019 Jan; 61(1):75-81. PubMed ID: 30058069
[TBL] [Abstract][Full Text] [Related]
9. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.
Lamb MM; West NA; Ouyang L; Yang M; Weitzenkamp D; James K; Ciafaloni E; Pandya S; DiGuiseppi C;
J Pediatr; 2016 Jun; 173():207-213.e3. PubMed ID: 27039228
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
[TBL] [Abstract][Full Text] [Related]
12. Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.
Lit L; Sharp FR; Apperson M; Liu DZ; Walker WL; Liao I; Xu H; Ander BP; Wong B
Pharmacogenomics J; 2009 Dec; 9(6):411-8. PubMed ID: 19488064
[TBL] [Abstract][Full Text] [Related]
13. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.
Matthews DJ; James KA; Miller LA; Pandya S; Campbell KA; Ciafaloni E; Mathews KD; Miller TM; Cunniff C; Meaney FJ; Druschel CM; Romitti PA; Fox DJ;
J Child Neurol; 2010 Nov; 25(11):1319-24. PubMed ID: 20207610
[TBL] [Abstract][Full Text] [Related]
14. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
[TBL] [Abstract][Full Text] [Related]
15. Psychosocial adjustment in males with Duchenne muscular dystrophy: psychometric properties and clinical utility of a parent-report questionnaire.
Hendriksen JG; Poysky JT; Schrans DG; Schouten EG; Aldenkamp AP; Vles JS
J Pediatr Psychol; 2009; 34(1):69-78. PubMed ID: 18650207
[TBL] [Abstract][Full Text] [Related]
16. Health status of boys with Duchenne muscular dystrophy: a parent's perspective.
Bray P; Bundy AC; Ryan MM; North KN; Burns J
J Paediatr Child Health; 2011 Aug; 47(8):557-62. PubMed ID: 21392149
[TBL] [Abstract][Full Text] [Related]
17. Psychosocial adjustment in adults with Duchenne muscular dystrophy: A pilot study on a shortened parent-report questionnaire.
Weerkamp PMM; Collin P; Maas RJ; Vermeulen RJ; Klinkenberg S; Hendriksen JGM
Neuromuscul Disord; 2022 Feb; 32(2):159-165. PubMed ID: 35067422
[TBL] [Abstract][Full Text] [Related]
18. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry.
Cowen L; Mancini M; Martin A; Lucas A; Donovan JM
BMC Neurol; 2019 May; 19(1):84. PubMed ID: 31046703
[TBL] [Abstract][Full Text] [Related]
19. Towards a short questionnaire for stepwise assessment of upper limb function, pain and stiffness in Duchenne muscular dystrophy.
Janssen MMHP; Geurts ACH; de Groot IJM
Disabil Rehabil; 2018 Apr; 40(7):842-847. PubMed ID: 28084836
[TBL] [Abstract][Full Text] [Related]
20. Impact of corticotherapy, nutrition, and sleep disorder on quality of life of patients with Duchenne muscular dystrophy.
Jeronimo G; Nozoe KT; Polesel DN; Moreira GA; Tufik S; Andersen ML
Nutrition; 2016 Mar; 32(3):391-3. PubMed ID: 26701140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
